Main outcome measure(s): Quality-adjusted life years (QALYs) were calculated using the 12-Item Short Form Health Survey, the Quality of Well Being Scale, and by converting depression-free days to QALYs. The base case analysis used outpatient, pharmacy, patient, and intervention costs. Cost-effectiveness was calculated using incremental cost effectiveness ratios (ICERs) and net health benefit (NHB). ICER distributions were generated using nonparametric bootstrap with replacement sampling.
INTRODUCTION
Depression is the single most common mental health condition seen in non-mental health settings. [1] Collaborative care for depression is effective [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and cost-effective in adult primary care, [14] [15] [16] [17] [18] [19] [20] [21] but many patients are seen outside primary care. It is less clear whether collaborative care for depression is effective in specialty care, few studies have been completed on this topic to date. [22, 23] Even more unclear is whether collaborative care for depression is cost-effective outside of primary care, because the cost profiles of specialty care providers and the services they provide are significantly different from those seen in primary care.
We chose Human Immunodeficiency Virus (HIV) as our test case because it is similar to a primary care setting in that many HIV providers often provide whole person care, not just HIV care. Also, depression is associated with nonadherence to HIV medication regimens and decreased immune functioning which can lead to accelerated HIV progression and increased risk of mortality. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Because depression can be effectively managed, it is a modifiable risk factor for the progression of HIV. [34] [35] [36] We chose the Veterans Health Administration (VHA) because it is the largest provider of HIV care in the nation [37] and it has a long history of mental health delivery innovation. As previously reported, the HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) intervention described in more detail below resulted in a significant increase in depression-free days and decrease in HIV symptom severity compared to usual care. [22] To our knowledge this is the first cost-effectiveness analysis of a collaborative care intervention for depression set in a specialty physical healthcare setting.
METHODS STUDY SETTING AND ENROLLMENT PROCEDURES
The intervention, methods, and clinical outcomes of the HITIDES study have been described in detail elsewhere. [22] To summarize, the HITIDES study was a randomized controlled implementation and effectiveness trial comparing depression collaborative care with enhanced usual care in three VA HIV specialty clinics. [38] Depression screening was implemented as part of usual care at all sites. [22] USUAL CARE DESCRIPTION All clinic site healthcare providers participating in the study received one hour of training in the detection and management of depression in patients with HIV and were also instructed in referral procedures for specialty A C C E P T E D mental healthcare at their site. These procedures included the suggestion of at least one failed depression treatment trial before referral. Usual care consisted of depression treatment by HIV or mental health clinicians without involvement from the HITIDES depression care team.
HITIDES INTERVENTION DESCRIPTION
A more detailed description of the intervention has been published elsewhere. [22] The HITIDES intervention involved collaboration between on-site HIV providers and an off-site HITIDES depression team comprised of a registered nurse depression care manager (DCM), clinical pharmacist, and psychiatrist (J.M.P). The HITIDES depression care support team was located off-site at the Central Arkansas Veterans Healthcare System in Little Rock, AR and met weekly or as needed either in-person or via telephone to discuss patients who were not responding to current depression treatment. All clinical communications with care providers took place in the electronic medical record progress notes. The DCM was solely responsible for communication with patients which was done exclusively via telephone. The HITIDES care team provided treatment suggestions to the clinicians responsible for direct patient care; all treatment decisions were ultimately left to on-site treatment providers.
Patients received the following intervention components from the DCM via a telephone encounter: participant education and activation, [39] assessment of treatment barriers and possible resolutions, depression symptom and treatment monitoring, substance abuse monitoring, and instruction in self-management (e.g., encouraging patients to exercise and participate in social activities). [4, 40] The DCM used standardized instruction scripts, which were supported by the Web-based decision support system NetDSS (available at https://www.netdss.net) during these telephone encounters. [41] The intervention used a stepped-care model for depression treatment [2] and specific treatment recommendations were based on the Texas Medication Algorithm Project [42] and the VA/Department of Defense Depression Treatment Guidelines. [43] DATA COLLECTION Baseline, 6-and 12-month data were collected by telephone interviewers who were blinded to treatment assignment and used computer-assisted assessments. At baseline, demographics, depression history, and chronic physical health conditions were measured using the Depression Outcomes Module. [44, 45] Mental health comorbidity was measured using the Mini International Neuropsychiatric Interview. [46, 47] Acceptability of antidepressant treatment was A C C E P T E D measured using an item developed for the Quality Improvement for Depression studies. [6, 48] Follow-up data-collection interviews were completed for 226/249 participants (90.8%) at 6 months and 215/249 (86.3%) at 12 months. QALYs from fully depressed to fully asymptomatic. DFDs and DFD QALYs were calculated using area under the curve calculations of baseline, 6-month, and 12-month data. [50, 51] Generic QALYs were calculated using the SF-12 standard gamble to QALY conversion formula [52] and the QWB scale. [53, 54] Intervention costs, healthcare expenditures, and patient costs were collected to assess the cost of the intervention from a societal perspective. Intervention costs included both fixed and variable costs. We included only DCM training as a net fixed intervention cost because the other fixed intervention costs were attributed to participants in both the intervention and usual care groups. Variable intervention costs included the time spent by intervention personnel delivering the intervention (e.g. time spent preparing and delivering the intervention, entering progress notes into the medical record, and attending intervention team meetings). These costs were calculated separately for the DCM, clinical pharmacist, and psychiatrist based on an hourly rate calculated from their respective VA salaries and fringe costs. Total intervention costs were estimated at $557 per intervention participant ($68,503/123).
Healthcare expenditures were assessed using VA Decision Support System data. This system uses an activitybased costing allocation method and includes fixed direct, variable direct, and fixed indirect costs. While the cost estimates have not been validated via micro-costing, DSS provides a useful proxy for encounter cost that is helpful to researchers. Outpatient expenditures for the base case analysis were organized in the following groups by clinic type (i.e., primary stop code): primary care, infectious disease, mental health, substance abuse, other medical specialty, and ancillary (including laboratory orders and radiography). Outpatient medication data were divided into HIV-related, depressionrelated, and other. Inpatient encounter data were used for secondary cost per QALY analyses. Patient travel and time expenditures were calculated based on self-reported time spent at 6-and 12-month follow-up interviews and income A C C E P T E D information collected at baseline. Expenditures were not discounted because of the relatively short 12-month time horizon of the study.
STATISTICAL ANALYSIS
We utilized an intent-to-treat analysis at the patient level. We performed a power calculation assuming an 11% difference in the percentage of responders between intervention and usual care using a 1-tailed t test (α = .05). A sample size of 280 (140 subjects per arm) would provide 74% power. Independent variables with missing values were imputed using multiple imputation methods. [55] _ENREF_57 Owing to the large number of available covariates and the use of multiple imputation methods, only those covariates found to significantly predict dependent variables at p<0.10 in bivariate analyses were included in multivariate analyses. After model specification was finalized, healthcare costs for the year prior to patient baseline assessment were added as a covariate to expenditure models.
Due to skewness from several high cost outliers the expenditure outcomes were non-normally distributed, so generalized linear models (GLMs) were utilized. [56] _ENREF_58 We ran 7 GLMs with normal, gamma, or inverse normal distributions and identity, logarithm, or square root link functions using a consistent specification of independent variables. The GLM regression with a gamma distribution and identity link function fit the expenditure data most appropriately. Using a similar procedure, the GLM regression with an inverse normal distribution and log link fit the DFD QALY data best, while gamma with identity link was used for both SF-12 and QWB derived QALYs.
Based on the coefficients from the GLM regressions for the specified independent variables and the covariate values for each participant, we calculated two predicted expenditures for each participant to determine the incremental treatment effect on costs. [57] The first expenditure prediction was if the participant had been randomized to the intervention (factual for intervention patients and counterfactual for usual care), and the second expenditure prediction was as if the participant had been randomized to usual care (counterfactual for intervention patients and factual for usual care). The difference between these two expenditure predictions represented the incremental effect of the intervention on expenditures for a particular participant because all covariate effects were identical for the two estimates for a given patient. We then averaged the difference between the two predicted values for each participant and across all participants to generate an incremental effect in the entire sample.
A C C E P T E D
The point estimate of the original sample will be used for means [58] ; however, typical standard error estimation methods do not apply to incremental cost-effectiveness ratios (ICERs) for two reasons. First, the possibility of having zero or near zero denominators is non-negligible. Second, expenditure and effectiveness estimates are rarely independent. [58] Therefore, we ran 1000 replications of nonparametric bootstrap with replacement model to generate an empirical joint distribution of incremental expenditures and QALYs. [58, 59] We then constructed acceptability curves representing the probability of falling below ICER thresholds ranging from 0 to $100,000 per QALY for each clinical outcome: DFD- In addition, we calculated the net health benefit (NHB) as suggested by Stinnett and Mullahy [61] to assist in the interpretation of [61] a negative (ICER). [58] NHB is calculated by dividing the marginal cost of the program by a costeffectiveness threshold (e.g. $50,000/QALY) and subtracting the result from the marginal effectiveness of the program (e.g. QALY difference). If the NHB is positive then the intervention is deemed cost-effective compared to the threshold used and should be selected for implementation. Otherwise, more health improvements could be attained by forgoing the intervention and investing in programs that are at least marginally cost-effective.
RESULTS
Baseline sociodemographic, clinical, and depression-related variables are presented in Table 1 . In general, patients were middle-aged, predominantly African-American, single, males with high levels of physical and mental health comorbidity in addition to moderate HIV symptoms. The only group differences at baseline were intervention patients had lower QWB-SA scores (0.44 vs. 0.49, p<0.01) and higher physical health comorbidity scores (3.8 vs. 3.2, p<0.05). Table 2 summarizes intervention and healthcare costs incurred by patients in the intervention and usual care groups. Healthcare costs were broken into outpatient (e.g. primary care, infectious disease, mental health, etc.) and pharmacy costs (HIV-related, depression-related, and other). The only statistically significant unadjusted difference in healthcare costs either before or after the intervention was higher post-intervention infectious disease outpatient costs for the intervention group ($3427 vs. $2585), indicating that intervention patients had more infectious disease visits than usual care patients. Total unadjusted healthcare expenditures increased an average $1150 for usual care patients and decreased $840 for intervention patients. After adjustment for case mix variables the overall intervention was cost saving, specifically including outpatient and pharmacy costs resulted in cost savings of $1368 (p<0.01) ( Table 3) . When inpatient A C C E P T E D costs were added for a secondary analysis the cost savings for the intervention was $534, but no longer statistically significant. Inpatient costs were included in a secondary analysis because of the generally highly skewed distribution for these costs; this approach is consistent with the literature. [17-19, 62, 63] As reported previously, the intervention resulted in 19.3 (p<0.01) additional DFDs over usual care. note there were significant differences at 6-month follow-up but not at 12-months. [22] All mean ICERs taken from the original sample were negative (Table 3) . Each of the NHB calculations using the $50,000/QALY threshold were positive for the intervention ranging from 0.037 QALYs for the QWB-SA QALYs to 0.048 QALYs for the DFD 0.4 to QALY conversion (Table 3) . NHB analysis of the disease-specific DFD measure was also positive further supporting the cost-effectiveness of the intervention (156 additional DFDs). Figure 1 gives the ICER distribution for the bootstrapped sample. Using the $50,000/QALY threshold, the base case analysis is cost-effective for 97% of the samples. Treatments that show ICERs less than $20,000/QALY are typically recommended for rapid dissemination into healthcare systems. [62] In our base case analysis, there is a 96.4% probability that the HITIDES intervention will cost less than $20,000/QALY and 77.8% probability that it will be cost saving. The acceptability curves for all four QALY measures are presented in Figure 2 and the probability of being less than $50,000/QALY varies between 82-97%, depending on the QALY measure.
DISCUSSION
The HITIDES intervention demonstrated improved outcomes and decreased costs compared to usual care over one year. Whereas depression and HIV symptom severity differences were statistically significant at 6-months, the QALY differences over 12-months were not. As Glick notes however, the lack of significant QALY differences
A C C E P T E D
represents "'absence of evidence of a difference' and not 'evidence of absence of a difference'". [64] For this reason, healthcare economists recommend evaluating the joint distribution of cost and effectiveness (e.g., incremental costeffectiveness plane or acceptability curve) in order to identify situations where the examination of clinical effect and cost simultaneously indicates clear advantages for one intervention over another. [64] [65] [66] As evidenced by our bootstrapped sample, despite the small QALY difference, the intervention was cost-effective in 97% of replications.
Cost per QALY estimates for collaborative depression care in non-veteran populations range from $3,303/QALY to $67,225/QALY adjusted to 2013 dollars and using only outpatient costs. [19, 20, 49, 63, 67] In the VA, cost per quality estimates range from $67,965/QALY to $103,319/QALY, adjusted to 2013 dollars. [17, 68] These cost per QALY estimates indicate that the collaborative care interventions cost more and resulted in better outcomes than usual care.
Other studies have examined subsamples of patients with depression. [19] Katon et al found that a multi-condition collaborative treatment program for depression, diabetes, and coronary heart disease was both effective (114 additional DFDs, 0.335 QALYS over a two year period) and cost-saving. [69] In another subgroup of_ENREF_62 patients with depression and diabetes, collaborative care was associated with substantially lower non-mental health medication and outpatient costs and cost per QALY ratios ranged from $261 to $524 per QALY (2013 dollars)._ENREF_63 [62] _ENREF_21These findings of cost-effective or cost-savings interventions in complex primary care patients suggests that collaborative care interventions may be particularly cost-effective for comorbid high cost patients. This situation is especially true in the HIV clinic where the HITIDES intervention was implemented. Total outpatient and pharmacy costs averaged $25,381 in the year prior to the intervention; this is substantially higher than that seen in the multi-condition cohort ($10,026).
The cost savings associated with the HITIDES intervention appears to be attributable to lower HIV medication costs and ancillary (e.g. laboratory, radiography, etc.) costs. Couple this finding with the fact that the intervention group had more HIV clinic visits and lower HIV symptom severity [22] and the interpretation of these findings could be that HIV symptoms were better controlled in intervention patients requiring less expensive HIV medication and laboratory monitoring. Of note, mental health costs are not significantly different between the two groups before or after the intervention signifying no substitution for mental health care by the intervention. The implication of this finding is that a wider roll-out of this intervention in VA HIV clinics could result in improved outcomes and cost savings. Further, given A C C E P T E D the demographic similarity between VA and non-VA HIV clinics, [70] similar results may be possible in non-VA HIV clinic settings.
Since the NHB of the HITIDES intervention is positive then it is cost-effective compared to a "marginally costeffective" program and should be selected for implementation. NHB findings for all outcome measures were positive, providing additional benefits to Veterans, supporting the case for implementation. Further, interventions that result in cost-effectiveness ratios less than $20,000 per QALY are recommended for rapid implementation into healthcare systems and the HITIDES intervention certainly meets this criterion. [71] Collaborative care approaches to depression management in primary care settings have been shown to be cost effective and associated with greater patient satisfaction outcomes. [3, 69] However, HIV clinics may be considered the patient's medical home and may not be located in primary care clinics. Therefore, considering available resources, HIV clinics could obtain depression collaborative care from on-site resources (within the HIV clinic or a nearby primary care clinic) or an off-site collaborative care team used in the HITIDES study. Another alternative is a hybrid team with both on-site and off-site collaborative care resources but the hybrid team was not tested in this study. While cost savings is not a prerequisite for implementation of a program to improve the mental health of patients, [72] _ENREF_68 the impressive results from the HITIDES intervention shifts the question from whether to implement to how best to implement this program. The depression collaborative care literature supports both on-site and off-site depression care teams. [73] _ENREF_69 The HITIDES intervention used an off-site team to cover three specialty clinics that differed across many characteristics (e.g. size, location, HIV provider mix, etc.). [38] _ENREF_70 The use of a single, centrally located care manager whose time could be devoted solely to this intervention may enhance intervention fidelity and introduce efficiencies in both training and supervision costs.
This study has several limitations worth noting. First, although the VA is the largest single provider of HIV care in the world and largest managed care organization in the US, the results of this study may not be generalizable to systems of care that are less integrated or that do not use electronic medical records. However, as the healthcare system changes these differences may be diminish. While the demographic and clinical characteristics of VA patients are typically different from patients in other healthcare settings, this limitation is less important for patients with HIV where the population differences are less prominent. Additionally, the DSS cost data only includes care received in the VA system. While comprehensive HIV care was provided to both the usual care and intervention groups in the study, any care A C C E P T E D received outside the VA system would not be represented in our findings. This would be especially concerning for an older group of study subjects with eligibility for both Veterans benefits and Medicare, but with an average age around 50 in this study this concern is diminished. The HITIDES intervention utilized an off-site intervention team; the relationship or generalizability of this approach to that of an on-site team is unknown. Our base case analysis used the DFD to QALY conversion formula that has been used in other depression collaborative care studies; however, there is no gold standard effectiveness measure for depression studies. Therefore, several QALY measures were used including the DFD to QALY conversion and generic QALY measures. Our results suggest that the DFD 0.2 [conservative] to QALY conversion is more consistent with the results from generic QALY measures.
In conclusion, in a specialty physical health clinic this depression collaborative care intervention (HITIDES) was effective and cost-saving. This finding is consistent with other primary care depression collaborative care results in subgroups of patients with expensive physical health comorbidities. Implementation of off-site depression collaborative care programs in specialty care clinics or to targeted patients based on clinical characteristics may be a strategy that not only improves outcomes for patients, but also maximizes the efficient use of limited healthcare resources. e Mental health comorbidity was identified using the Mini International Neuropsychiatric Interview.
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